Table 1.
Baseline characteristics of 145 coronavirus disease 2019 (COVID-19) patients treated with molnupiravir.
| CHARACTERISTICS | Total Study Population |
|---|---|
| N = 145 (%) | |
| Age, years | 71.0 (59.0–80.8) |
| Sex, male | 88 (60.7) |
| McCabe Scale | |
| Non-fatal | 47 (32.4) |
| Ultimately fatal | 61 (42.1) |
| Rapidly fatal | 37 (25.5) |
| Comorbidity condition according to the Italian Medicine of Pharmacy | |
| Severe cardiovascular disease | 54 (37.2) |
| Primary or acquired immunodeficiency | 33 (22.8) |
| Oncological/onco-hematological disease in the active phase | 32 (22.1) |
| Severe pulmonary disease | 24 (16.6) |
| Obesity (BMI > 30) | 22 (15.2) |
| Uncompensated diabetes mellitus | 13 (9.0) |
| Chronic renal failure | 5 (3.4) |
| Charlson comorbidity index, median (IQR) | 2.0 (1.0–2.0) |
| Signs and symptoms | |
| Fever (Tc > 37.3) | 85 (58.6) |
| Cough | 62 (42.8) |
| Asthenia | 46 (31.7) |
| Sore throat | 34 (23.4) |
| Arthralgia-myalgia | 22 (15.2) |
| Congestion | 20 (13.8) |
| Headache | 7 (4.8) |
| Gastrointestinal symptoms | 4 (2.8) |
| Ageusia and anosmia | 1 (0.7) |
| Dyspnea | 1 (0.7) |
| Duration of symptoms before molnupiravir administration, median days (IQR) | 2 (1–3) |